Please contact us for more information or to learn if you are eligible to participate.
The primary goal of this study is to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
Principal Investigator | Fernando Membreno, MD |
Type of Trial | Prospective/Interventional |